Abstracts Archive - Page 1904 of 2607 - ACR Meeting Abstracts

Abstract Number: 491 • 2015 ACR/ARHP Annual Meeting
A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
Wan-Uk Kim¹, Yune-Jung Park², Seung-Ah Yoo³, Bong Ki Hong³, Gi myo Kim⁴, Susanna Choi⁵, Saseong Lee³ and Chul-Soo Cho⁶, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ³Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea, ⁴Institute of bone and joint diseases, Catholic university, seoul, South Korea, ⁵Institute of Bone and Joint diseases, The Catholic University of Korea, seoul, South Korea, ⁶Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: To optimize treatment for rheumatoid arthritis (RA), it is ideal to monitor disease activity on a daily basis such as glucose measurement since RA…
Abstract Number: 492 • 2015 ACR/ARHP Annual Meeting
Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
Andreea Borangiu¹, Diana Mazilu¹, Ioana Saulescu¹, Evelina Iachim², Laura Grosanu¹, Cosmin Constantinescu¹, Andra Balanescu¹, Denisa Predeteanu¹, Ruxandra Ionescu¹ and Daniela Opris¹, ¹University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Carol Davila Medicine and Pharmacy University, Bucharest, Romania
Background/Purpose: Correct assessment to biologics in rheumatoid arthritis (RA) patients is extremely important regarding future patient management. There is still an open debate about the…
Abstract Number: 493 • 2015 ACR/ARHP Annual Meeting
Diagnostic Delay in Early Arthritis: Ten Years-Experience of a Single Center
Francesca Benaglio, Silvia Balduzzi, Serena Bugatti, Garifallia Sakellariou, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS S. Matteo Foundation, Pavia, Italy, Pavia, Italy
Background/Purpose: In the last 10 years a big effort has been made to reduce the diagnostic delay in patients with early arthritis, in order to…
Abstract Number: 494 • 2015 ACR/ARHP Annual Meeting
High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab
Maria Joao Gonçalves^1,2, Geraldine Cambridge³ and Maria J. Leandro³, ¹Rheumatology Department, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ²Rheumatology Department, Lisbon Academic Medical Centre, Lisbon, Portugal, ³Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: B cell depletion with rituximab (RTX) is an established treatment for RA. It was first introduced at UCL in 1998 and at this centre…
Abstract Number: 495 • 2015 ACR/ARHP Annual Meeting
Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Antonio Manzo¹, Serena Bugatti¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Barbara Vitolo¹, Carlomaurizio Montecucco¹ and Roberto Caporali², ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of the…
Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Seung Min Jung¹, Ji Yeon Lee¹, Jung Hee Koh¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Chong-Hyeon Yoon¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…
Abstract Number: 498 • 2015 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Gerolamo Bianchi¹, Antonio Carletto², Oscar M. Epis³, Crescenzio Scioscia⁴, Angelo Semeraro⁵, Chiara Donati⁶, Laura Bazzichi⁷, Giovanni Lapadula⁸, Luigi Sinigaglia⁹ and Andrea Lo Monaco¹⁰, ¹Div Reumatologia, Ospedale La Colletta, Genoa, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy, ³Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy, ⁴DIM - Sezione di Reuamtologia Università degli Studi di Bari "Aldo Moro", Bari, Italy, ⁵Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ⁶Roche S.p.A., Monza, Italy, ⁷Division of Reumatology, Univeristy of Pisa, Pisa, Italy, ⁸D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁹Rheumatology Dep, I.O.G. Pini, Milan, Italy, ¹⁰Ospedale S. Anna, Ferrara, Italy
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the non-adherence to therapy may impair the clinical outcomes, being often associated with the disease flare and…
Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 501 • 2015 ACR/ARHP Annual Meeting
Change in RF Titers Reflects RA Disease Activity and Predicts Therapeutic Response during TNF Inhibitor Therapy; Patients with a Continuous Reduction of Serum RF Levels Show Good Response
Takayoshi Owada, Kazuhiro Kurasawa, Yuta Takamura, Yumeko Namiki, Ayae Tanaka, Ryutaro Yamazaki, Harutsugu Okada, Satoko Arai, Reika Maezawa, Keiko Hatanaka and Yoshiki Ishii, Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Serum RF was detected in 26-90% of RA patients, and high-titer RF has been shown a poor prognosis factor in RA and predictor of…
Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Karen Boyle³, Lynette Keyes-Elstein³, Beverly Welch⁴, Ellen Goldmuntz⁵ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…
Abstract Number: 503 • 2015 ACR/ARHP Annual Meeting
Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
T. Martijn Kuijper¹, J.J. Luime², P.H.P. de Jong³, A. H. Gerards⁴, Derkjen van Zeben⁵, I. Tchetverikov⁶, P.B.J. de Sonnaville⁷, M. van Krugten⁸, B. Grillet⁹, Mieke Hazes¹⁰ and A.E.A.M. Weel^11,12, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁷Oosterschelde Hospital, Goes, Netherlands, ⁸Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁹Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ¹⁰Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ¹¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Early and intensive treatment with DMARDs are essential for remission induction in newly diagnosed RA patients. However, demographic, psychosocial and disease related factors may…
Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…
Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Yusuf Yazici¹, Hannah Bernstein¹ and Christopher Swearingen², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].